The IL-17RE antibody (Clone 934832) is a mouse monoclonal IgG2b antibody that specifically binds to the extracellular domain of human IL-17RE (Met1-His454) . It recognizes a 70 kDa transmembrane protein expressed on keratinocytes, mucosal epithelial cells, Th17 cells, and γδ T cells . The antibody’s epitope resides within amino acids 115-454, which share 79% sequence identity with murine IL-17RE .
Receptor Localization: Used in flow cytometry to confirm IL-17RE surface expression on transfected HEK293 cells (Figure 1A) .
Signaling Inhibition: Blocks IL-17C binding to the IL-17RA/RE heterodimer, reducing downstream NF-κB and MAPK activation in keratinocytes .
Th17 Cell Analysis: Identifies IL-17RE+ Th17 cells in autoimmune models, showing enhanced receptor expression upon stimulation with IL-6/TGF-β/IL-23 .
3.2 Disease Models
Table 2: Key Research Findings Using IL-17RE Antibody
Therapeutic targeting of the IL-17C/RE axis is under investigation for:
Psoriatic arthritis: Antibody-mediated IL-17RE inhibition reduces IL-17A/F production by 74% in synovial fluid cultures .
COPD: Neutralizing IL-17RE decreases airway epithelial CXCL1/5 secretion by 89% in LPS-challenged models .
Anti-TNF-α Complications: Counteracts paradoxical skin inflammation in IBD patients on biologics .
Negative Control: Non-transfected HEK293 cells show <5% background staining .
Isotype Control: Mouse IgG2b (Catalog #MAB002) used to set flow cytometry quadrants .
Optimization Notes:
Requires titrated secondary antibody concentrations (e.g., 1:200 dilution for APC-conjugated anti-mouse IgG) .
Prolonged storage at 4°C causes 18% activity loss over 6 months .
IL17RE is a specific functional receptor for IL17C. It may signal through the NF-kappa-B and MAPK pathways. IL17RE may require TRAF3IP2/ACT1 for signaling and serves as a crucial regulator in innate immunity against bacterial pathogens. Isoform 2 and isoform 4 may exist as either cytoplasmic inactive or dominant active forms. Isoforms 3 and 5 may function as soluble decoy receptors.